ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133)

Published:2012-04-22 Issue:Meeting Abstracts 1 Volume:78 Page:P01.133-P01.133
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Calabresi P.,Kieseier B.,Arnold D.,Balcer L.,Boyko A.,Pelletier J.,Zhu Y.,Deykin A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic and safety issues for multiple sclerosis pharmacotherapy – opportunities for personalised medicine;Expert Opinion on Drug Metabolism & Toxicology;2014-06-09

2. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis;Multiple Sclerosis Journal;2014-05-08

3. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis;Expert Opinion on Drug Metabolism & Toxicology;2014-03

4. Emerging injectable therapies for multiple sclerosis;The Lancet Neurology;2013-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP